TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 0:14 · $HIMS · Hims & Hers HUGE Acquisition News! | $HIMS
episode briefing
Asymmetric Investing

Hims & Hers HUGE Acquisition News! | $HIMS

2026-02-19 · 4 company · 3 thematic
sentiment
0 bull1 bear3 neu
speakers
travis hoium

Travis Hoium hosts the Asymmetric Investing podcast/YouTube channel and manages the Asymmetric portfolio. He conducts fundamental research using Fiscal AI and focuses on platform business models, healthcare technology, and consumer subscription businesses. He discloses holding Hims & Hers as one of his largest positions.

quote
“This definitely levers up the balance sheet. It uses up a lot of that cash that they raised last year. And now you have a company that's operating with debt. So, it's not a phenomenal, it's not a pristine balance sheet like you had even si…”
—travis hoium
now playing · $HIMS
$HIMS···neutral· mediumtravis hoium
Travis Holm analyzes HIMS $1.15B Eucalyptus acquisition: balance sheet risk vs international platform upside
The Eucalyptus acquisition leverages up HIMS' balance sheet using cash from last year's convertible notes, removing the pristine balance sheet cushion amid the Novo Nordisk lawsui…
$EUCALYPTUSneutral· mediumtravis hoium
Eucalyptus acquired by HIMS for $1.15B to expand into Australia, Japan, UK, Germany, Canada
Eucalyptus brings $450M revenue run-rate and established presence in Australia, Japan, UK, Germany, and Canada, serving as the vehicle for HIMS' international aggregator strategy.…
$ZAVAneutral· lowtravis hoium
Zava acquisition last year part of HIMS international rollout before Eucalyptus deal
Zava was HIMS' first international acquisition, establishing a foothold in Europe before the larger Eucalyptus deal expanded the footprint further.
$NVO···bearish· mediumtravis hoium
Novo Nordisk lawsuit creates downside risk for HIMS if GLP-1 compounding challenged
The ongoing lawsuit with Novo Nordisk poses material downside risk — if it goes poorly, it could be costly and hurt HIMS' growth and margins, especially as the company leverages u…